Andrew Ambrosy
Kaiser Permanente
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew Ambrosy as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:33 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07298993 · Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)Weill Medical College of Cornell University · enrolling by invitation · Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- DEPRESCRIBE-HFPEFR01AG091005 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · fiscal years 2025 to 2026 · $680,686 awarded in 2026Grant number is on one of their registry trials
- AI-Enabled Echocardiographic Biomarkers and Real-World Data for Predicting Cancer Therapy-Related Cardiac DysfunctionU01FD008704 · FDA · KAISER FOUNDATION RESEARCH INSTITUTE · fiscal years 2025 · $1,498,464 awarded in 2025Same name and institution; not confirmed by an ID
- Harnessing Artificial Intelligence and Deep Learning to Determine a Coronary Artery Calcium Estimate in Patients with No History of AtheroSclerotic CardioVascular Disease (HIDDEN-ASCVD) StudyR01HL173866 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · fiscal years 2025 · $3,918,561 awarded in 2025Same name and institution; not confirmed by an ID
- Outpatient Worsening Heart Failure in an Integrated Health Care Delivery System: An Innovative Approach to Characterizing a Novel Clinical EntityK23HL150159 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · fiscal years 2020 to 2024 · $193,320 awarded in 2024Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:33 UTC. The ranking covers the 200 most relevant of 50 PubMed records, and a shared surname and initials can bring in a namesake. All 50 on PubMed
- Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.N Engl J Med · 2019981 citationsRCR 43.3
- Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.Circulation · 2019149 citationsRCR 5.8
- 116 citationsRCR 3.3
- Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.Circ Heart Fail · 2012115 citationsRCR 3.9
- Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.Eur J Heart Fail · 2013113 citationsRCR 3.5
- Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.JACC Heart Fail · 2017113 citationsRCR 4.7
- 85 citationsRCR 2.6
- Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.J Am Coll Cardiol · 201780 citationsRCR 2.5
- Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.JAMA Cardiol · 202073 citationsRCR 3.3
- Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.Circ Heart Fail · 201365 citationsRCR 2.4